The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).
Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...
Bybit, the world's second-largest cryptocurrency exchange by trading volume, officially marks the 3rd anniversary of its P2P ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan ...
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC) Zai Lab Limited today announced the U.S. Food and Drug ...
The FDA’s approval of Amgen’s DLL3 × CD3 bispecific antibody tarlatamab (Imdelltra) last year validated the DLL3 cancer target, demonstrating its approvability in extensive-stage small-cell ...
Amado, M.D., President, Head of Global Research and Development at Zai Lab. “Building on the promising findings from our ongoing clinical trials for ZL-1310, this new collaboration demonstrates our ...
“Building on the promising findings from our ongoing clinical trials for ZL-1310, this new collaboration demonstrates our continued focus on developing cancer therapies with ADC drugs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback